

For the Primer, visit [doi:10.1038/nrdp.2015.10](https://doi.org/10.1038/nrdp.2015.10)

➔ Cystic fibrosis is a disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene, which encodes a transmembrane chloride and bicarbonate ion channel on the apical surface of glandular epithelial cells throughout the body. Although *CFTR* dysfunction affects many organs, lung disease is responsible for the vast majority of morbidity and mortality.

SCREENING


Cystic fibrosis is increasingly being diagnosed earlier in life because of the introduction of newborn screening in past 20 years. In 2010, over half of the patients with cystic fibrosis in the United States were diagnosed shortly after birth. Newborn screening offers the ability to manage lung health before symptoms develop.

DIAGNOSIS

Screen-positive newborns can be diagnosed by a sweat test; individuals with cystic fibrosis have more chloride in their sweat than unaffected individuals. Identifying lung disease relies on lung function measurements, imaging and bronchialveolar lavage, which is used to detect infection and inflammation. Genetic testing is an important part of modern diagnostics, because mutation-specific therapy is an increasing reality.



Rx MANAGEMENT



Novel strategies that directly target the *CFTR* channel abnormality are becoming available

Potentiator and corrector therapies are increasingly being used

OUTLOOK

Many modifier genes might be active in cystic fibrosis, influencing intracellular pathways or other ion channels. Understanding these functions


might help to predict the variability in responses to genotype-specific treatments, and to design better treatments. Indeed, finding therapeutic

strategies for the aspects of the disease beyond *CFTR* dysfunction will be important to maintain lung health in patients with cystic fibrosis.

MECHANISMS

CFTR mutations cause various molecular defects, including no production of functional protein, absent or diminished protein processing, defective ion gating or decreased ion conductance. In the lungs, *CFTR* dysfunction results in mucus accumulation that obstructs the airway lumen and diminishes mucociliary clearance. The lack of bicarbonate secretion leads to an acidic pH of the airway surface liquid in cystic fibrosis, which might contribute to defective bacterial killing — predisposing patients to infection.

In extrapulmonary organs (for example, the pancreas and liver), ductular obstruction is also observed



QUALITY OF LIFE

Cystic fibrosis is a multisystem disease that affects many organs, but over the past 20 years health outcomes and lifespan have improved dramatically with the introduction of long-term therapies. However, treatment complexity and perceived burden are concerns among patients, and might affect adherence to treatment. Modern trials now routinely use reliable and valid instruments to assess quality-of-life domains in cystic fibrosis.

! The presence of one *CFTR* allele that is at least partially active can vastly improve clinical outcome